Author Affiliations: Department of Ophthalmology, St Franziskus Hospital, Muenster (Drs Schumacher and Heiligenhaus); Departments of Pediatrics (Drs Lohr and Wagner), Ophthalmology (Drs Kaup and Walter), and Pathology (Dr Perez-Bouza), University Hospital RWTH Aachen, Aachen; and Department of Pediatric Rheumatology, Institute of Immunology, University of Muenster, Muenster (Dr Roth), Germany.
Necrotizing sarcoid granulomatosis (NSG) is a rare systemic disease characterized by confluent sarcoid-like granulomas with necrotic areas and a variable degree of vasculitis. First described by Liebow1 in 1973, NSG can be classified as a disease showing features of Wegener granulomatosis and sarcoidosis. The etiology and pathogenesis of NSG are so far unknown; it is considered to be unrelated to infection. Necrotizing sarcoid granulomatosis is an extremely rare disease in childhood, with only a few cases reported to date.2 In this case report, we describe 3 children of African origin who were diagnosed with an ocular manifestation of NSG.
Symptoms and important diagnostic results are summarized in the Table. Our institution does not require approval by the local ethics committees for chart review studies.
Patient 1 is a 9-year-old boy of half African, half Caucasian origin, who was born in Germany and grew up there. His father was born in Ghana, Africa, and is known to have sarcoidosis (Table). The ophthalmologic examination revealed a regular anterior segment of the eye, but chorioretinal infiltrates with retinal vascular occlusions and perivasular exudation were observed bilaterally. The histopathologic findings are shown in Figure 1, and the fluorescein and indocyanine green angiographic observations are documented in Figure 2. The child received treatment with corticosteroids (prednisolone) initially 2 mg/kg body weight for 4 weeks, which was then reduced in a stepwise fashion. Subsequently, the ocular findings improved, and the perivasular exudation disappeared after 7 months. After a follow-up of 15 months, the boy presently does not show any symptoms and is in excellent condition.
Figure 1. Lymph node biopsy of patient 1 showing multiple granulomas. A, Hematoxylin-eosin (HE) stain; arrows indicate granulomas. B, HE stain in more detail, with 1 granuloma with necrosis (asterisk) and a Langerhans giant cell (arrow).
Figure 2. Fluorescein and indocyanine green (ICG) angiographic observation in patient 1 from the right eye, both at 5.09 minutes. Fluorescein angiogram (FA) shows retinal vascular occlusions and shunt formation in the fundus periphery (arrowheads) with retinal leakage (arrow). By ICG angiography, hypofluorescent spots can be observed in the choroid (arrows), likely from inflammatory infiltration.
Patient 2 is a 10-year-old boy of African origin who was born in Germany and grew up there (Table). The ophthalmologic examination showed bilateral granulomatous panuveitis with vasculitic retinal infiltrates. Systemic treatment with prednisolone, 2 mg/kg body weight, was instituted. Complete inflammatory quiescence was obtained after a follow-up of 13 months with this therapy.
Patient 3 is an 11-year-old African girl who was born in Germany and grew up there (Table). The parents are from Congo, Africa. The ophthalmologic examination showed bilateral granulomatous panuveitis with mutton-fat keratic precipitates, cells in the aqueous humor, iris granulomas, posterior synechiae (Figure 3), vitritis, chorioretinal infiltrates, and retinal vascular exudation. She received treatment with prednisolone, initially 1 mg/kg body weight, which was subsequently tapered over 7 weeks to a dosage less than 0.1 mg/kg body weight, in combination with azathioprine (1.5 mg/kg body weight). The ocular findings improved thereafter. After 18 months, no retinal infiltrates were present. Currently, her uveitis is in complete remission.
Figure 3. Anterior segment photography in patient 3 showing posterior synechiae (arrowheads) and mutton-fat keratic precipitates (arrows) of the right (A) and left (B) eyes.
Only a few reports have described involvement of the eyes in necrotizing sarcoid granulomatosis.3,4 Posterior segment manifestations have rarely been documented. Our case series describes the chorioretinal involvement in detail, including the findings from fluorescein and indocyanine green studies.
Granulomatous inflammation and caseating or noncaseating necrosis plus vasculitis seen on biopsy of enlarged lymph nodes identified on computed tomography and magnetic resonance imaging scans are not disease specific but meet the criteria for the diagnosis of extrapulmonary NSG.1,2 Regarding the finding of partially caseating necrosis in the setting of a pediatric patient, tuberculosis represented the most likely diagnosis in the differential, but all biopsy specimens were negative for bacteria, fungi, and acid-fast bacilli (typical and atypical mycobacteria) on histologic stains, cultures, and polymerase chain reaction assay. Histopathologically, caseating or noncaseating necrosis was atypical for sarcoidosis, and serum angiotensin-converting enzyme levels were negative in 2 of the 3 children. Nevertheless, increased angiotensin-converting enzyme levels are not a specific marker for sarcoidosis. Other causes for necrotizing granulomata were also excluded, including Wegener granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome, Crohn disease, infectious diseases (varicella zoster, leishmaniasis, and aspergillosis), Hodgkin lymphoma, and postsurgical granulomata.
It may be assumed that NSG might be a subtype of sarcoidosis. However, none of our patients had pulmonary findings consistent with sarcoidosis. The main characteristic that distinguishes sarcoidosis from NSG is necrosis in the center of the granulomas. This necrosis may arise from granulomatous vasculitis with progressive vessel occlusion. The retinal findings described for our patients reflect this histopathologic characteristic. The hypofluorescent spots that were seen in our patients in the indocyanine green studies are typical of granulomatous infiltrations in the choroid. In addition, mutton-fat keratic precipitates and the granuloma formation in the iris support the granulomatous character of the eye manifestation. Furthermore, the fluorescein features show the frank perivascular exudation that is typical for sarcoidosis and the retinal occlusion that may occur in patients with granulomatous uveitis. Taken together, these findings support the hypothesis that NSG may be a variant of sarcoidosis and not a clinical entity of its own.
Interestingly, all of our patients were of African origin. Presently, no data are available showing a higher incidence of NSG in Africans. Indeed, only 1 case report of NSG in an African patient has been published. One of our patients had a familial predisposition to sarcoidosis; his father has this disease. To our knowledge, so far only 1 instance of NSG has been described in which a positive family history of sarcoidosis was present.5
Necrotizing sarcoid granulomatosis is reported to respond very well to immunosuppressive treatment with corticosteroids. In patients 1 and 2, we observed a timely response to systemic administration of corticosteroids. Patient 3 had to be treated with azathioprine in addition to corticosteroids to achieve remission. All 3 patients went into remission, and the clinical and angiographic findings improved. However, it is important to follow up these patients because relapses have been reported after treatment was discontinued.
Correspondence: Arnd Heiligenhaus, MD, Department of Ophthalmology, St Franziskus Hospital, Uveitis-Center and Ophtha Lab, Hohenzollernring 74, 48145 Muenster, Germany (email@example.com).
Submitted for Publication: June 21, 2010; final revision received March 1, 2011; accepted March 2, 2011.
Author Contributions: The authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Schumacher and Lohr contributed equally to this work.
Financial Disclosure: None reported.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.